Literature DB >> 9826510

Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition.

P Dokurno1, P A Bates, H A Band, L M Stewart, J M Lally, J M Burchell, J Taylor-Papadimitriou, D Snary, M J Sternberg, P S Freemont.   

Abstract

The anti-breast tumour antibody SM3 has a high selectivity in reacting specifically with carcinoma-associated mucin. SM3 recognises the core repeating motif (Pro-Asp-Thr-Arg-Pro) of aberrantly glycosylated epithelial mucin MUC1, and has potential as a therapeutic and diagnostic tool. Here we report the crystal structure of the Fab fragment of SM3 in complex with a 13-residue MUC1 peptide antigen (Thr1P-Ser2P-Ala3P-Pro4P-Asp5P-Thr6P -Arg7P-Pro8P-Ala9P-Pro10P-Gly11P- Ser12P-Thr13P). The SM3-MUC1 peptide structure was solved by molecular replacement, and the current model is refined at 1.95 A resolution with an R-factor of 21.3% and R-free 28.3%. The MUC1 peptide is bound both by non-polar interactions and hydrogen bonds in an elongated groove in the antibody-combining site through interactions with Complimentarity Determining Regions (CDRs), three of the light chain (L1, L2, L3) and two of the heavy chain (H1 and H3). The conformation of the peptide is mainly extended with no discernable standard secondary structure. There is a single non-proline cis-peptide bond in H3 (Val95H-Gly96H-Gln97H-Phe98H-Ala101H-Ty r102H) between Gly96H and Gln97H, which appears to play a role in SM3-peptide antigen interactions, and represents the first such example within an antibody hypervariable loop. The SM3-MUC1 peptide structure has implications for rational therapeutic and diagnostic antibody engineering. Copyright 1998 Academic Press

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826510     DOI: 10.1006/jmbi.1998.2209

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  16 in total

1.  Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells.

Authors:  Ola Blixt; Olga I Lavrova; Dmitriy V Mazurov; Emiliano Cló; Stjepan K Kracun; Nicolai V Bovin; Alexander V Filatov
Journal:  Glycobiology       Date:  2011-12-05       Impact factor: 4.313

2.  Antibody recognition of a unique tumor-specific glycopeptide antigen.

Authors:  Cory L Brooks; Andrea Schietinger; Svetlana N Borisova; Peter Kufer; Mark Okon; Tomoko Hirama; C Roger Mackenzie; Lai-Xi Wang; Hans Schreiber; Stephen V Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

3.  Significance of Proline Residue on Short Mucin Peptide Interactions with Mouse MUC1 Monoclonal Antibody Studied by Saturation Transfer Difference NMR Spectroscopy.

Authors:  Cheng Her; William M Westler; Thao Yang
Journal:  JSM Chem       Date:  2013-10-17

4.  Androgen-dependent regulation of human MUC1 mucin expression.

Authors:  Stephen Mitchell; Paul Abel; Sanjeev Madaan; James Jeffs; Khurram Chaudhary; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

5.  Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds.

Authors:  Todd A Sulchek; Raymond W Friddle; Kevin Langry; Edmond Y Lau; Huguette Albrecht; Timothy V Ratto; Sally J DeNardo; Michael E Colvin; Aleksandr Noy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

6.  Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.

Authors:  Mohammadreza Movahedin; Teresa M Brooks; Nitin T Supekar; Naveen Gokanapudi; Geert-Jan Boons; Cory L Brooks
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

7.  Targeting Underglycosylated MUC1 for the Selective Capture of Highly Metastatic Breast Cancer Cells Under Flow.

Authors:  Yue Geng; Tait Takatani; Kimberly Yeh; Jong-Wei Hsu; Michael R King
Journal:  Cell Mol Bioeng       Date:  2013-05-22       Impact factor: 2.321

8.  Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.

Authors:  Wei-Chun Chiu; Ya-Ping Lai; Min-Yuan Chou
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

9.  Crystal structure of two anti-porphyrin antibodies with peroxidase activity.

Authors:  Victor Muñoz Robles; Jean-Didier Maréchal; Amel Bahloul; Marie-Agnès Sari; Jean-Pierre Mahy; Béatrice Golinelli-Pimpaneau
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

10.  Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade.

Authors:  Yue Geng; Kimberly Yeh; Tait Takatani; Michael R King
Journal:  Front Oncol       Date:  2012-07-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.